<DOC>
	<DOC>NCT00525668</DOC>
	<brief_summary>Hypothesis: Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).</brief_summary>
	<brief_title>Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)</brief_title>
	<detailed_description>This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>male and female subjects age 18 to 60 relapsingremitting course of MS stable treatment with glatiramer acetate at least 6 months prior to inclusion primary or secondary progressive forms of MS clinically relevant heart, lung, liver, kidney diseases regular hepatotoxic comedication drug addiction alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>inflammation</keyword>
	<keyword>neurodegeneration</keyword>
	<keyword>neuroprotection</keyword>
</DOC>